NACDS: Texas Attorney General Paxton rules wisely on state PBM reform’s enforceability
NACDS says “flimsy PBM excuses are dwindling, and for Texans and more Americans help is on the way”.
NACDS says “flimsy PBM excuses are dwindling, and for Texans and more Americans help is on the way”.
The company will collaborate with Henlius on HLX15 (daratumumab), a biosimilar candidate to Darzalex and Darzalex Faspro in the U.S. and Europe.
NACDS's Nourish My Health campaign highlights member pharmacies offering heart health services at over 25,000 locations nationwide.
The 340B program raises costs for employers and state and local governments by billions. Contract pharmacy legislation could increase those costs further.
Biosciences and Diagnostic Solutions to realize its full market potential as differentiated leader in Life Sciences Tools and Diagnostics, with robust innovation pipeline and headroom for growth in key sectors.
This partnership strengthens Kroger's commitment to accessible healthcare and affordable prescriptions.
Additionally, registration is open for NCPA’s 2025 Congressional Pharmacy Fly-In, taking place April 30 – May 1 in Alexandria, Va., and Washington, D.C.
Collaboration removes financial barriers to higher education and supports talent pipeline for future pharmacists.
NACDS is urging policymakers and stakeholders to prioritize policies that support these "Four Wins" to create a healthier America.
The film highlights the emotional and psychological challenges faced by individuals living with diabetes.
The committee voted for RFK Jr. 14-13, sending his nomination to the Senate floor for a vote, probably next week.
“This is not just about dollars and cents—it is about lives,” says AAM President Dan Leonard.
The Council’s first year delivers tangible solutions to strengthen pharmacy talent pipeline and transform the future of pharmacy.
The Somerset, N.J. facility encompasses over 50,000 sq ft of cGMP manufacturing space and is home to over 200 skilled scientists and technicians.
Journavx is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years.
“Professional associations, medical journal editors, the National Academy of Medicine and other leaders must speak out in defense of science and public health. Silence in this critical moment is the wrong choice.”